Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells†‡
Open Access
- 25 March 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 41 (4), 896-905
- https://doi.org/10.1002/hep.20630
Abstract
Phospholipase A2 IIA (PLA2IIA), which plays a crucial role in arachidonic acid metabolism and in inflammation, is upregulated under various pathological conditions, including in the gallbladder and gallbladder bile from patients with multiple cholesterol gallstones, in the liver and kidney of rats with cirrhosis, as well as in the colonic tissue of animals treated with a chemical carcinogen. The administration of ursodeoxycholic acid (UDCA) partially attenuated the PLA2IIA expression level in these different models. The aim of this study was to investigate the modulatory effect of UDCA on the PLA2IIA expression level at the cellular level. The HepG2 cells were selected to investigate the direct inhibitory effect of UDCA on PLA2IIA expression level. The proinflammatory cytokines (interleukin-6 and tumor necrosis factor α) -induced PLA2IIA expression in HepG2 cells was partially inhibited by the presence of UDCA in a dose-dependent fashion. The effect of UDCA on proinflammatory cytokines-induced PLA2IIA expression occurred at the transcriptional level. In addition, among the bile acids tested, this inhibitory effect was UDCA-specific. In conclusion, this study supports the possible alteration of arachidonic acid metabolism and PLA2IIA expression level, in particular, as the protective action of UDCA in patients with chronic liver disease. (HEPATOLOGY 2005;41:896–905.)Keywords
This publication has 45 references indexed in Scilit:
- The role of prostacyclin in patients with portal hypertensionLiver International, 2008
- Potentiation of Tumor Necrosis Factor α-induced Secreted Phospholipase A2 (sPLA2)-IIA Expression in Mesangial Cells by an Autocrine Loop Involving sPLA2 and Peroxisome Proliferator-activated Receptor α ActivationJournal of Biological Chemistry, 2003
- ATTENUATION OF ISCHEMIA AND REPERFUSION INJURY OF CANINE LIVERS BY INHIBITION OF TYPE II PHOSPHOLIPASE A2 WITH LY3297221Transplantation, 2001
- Induction of Secreted Type IIA Phospholipase A2 Gene Transcription by Interleukin-1βPublished by Elsevier ,2000
- Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stonesHepatology, 1998
- Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapyJournal of Gastroenterology and Hepatology, 1996
- Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in ratsCarcinogenesis: Integrative Cancer Research, 1996
- Cysteinyl Leukotrienes in the Urine of Patients With Liver DiseasesHepatology, 1994
- Positive and Negative Hepatic Regulation of the Human Type II Phospholipase A2 GeneBiochemistry, 1994
- Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis.Gut, 1977